Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024Expects to Begin Enrollment in Phase 3 Confirmatory Trial, RAMP 301, of Avutometinib and Defactinib in LGSOC in Q4 2023Presented Additional Patient Subgroup Data for the.
Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in H1 2024
Expects to Begin Enrollment in Phase 3 Confirmatory.
Planned Subgroup Analysis of RAMP 201 Data Showed Combination Demonstrated Robust Efficacy in Recurrent LGSOC Regardless of Number and Class of Prior Therapies Including After Poor Response to Prior TherapyLate-Breaking Abstract Featured as an Oral Presentation during a Plenary Session at the Annual Global Meeting o.
Mike Crowther Appointed Chief Commercial and Business Strategy Officer
David Mitchell Appointed Senior Vice President, Head of Regulatory Affairs
Dan Calkins Promoted to Chief Financial Officer.